Books > Medicine > Other branches of medicine > Pharmacology
|
Buy Now
Cancer Therapeutics - Experimental and Clinical Agents (Paperback, Softcover reprint of the original 1st ed. 1997)
Loot Price: R5,510
Discovery Miles 55 100
|
|
Cancer Therapeutics - Experimental and Clinical Agents (Paperback, Softcover reprint of the original 1st ed. 1997)
Series: Cancer Drug Discovery and Development
Expected to ship within 10 - 15 working days
|
Cancer drug discovery has been and continues to be a process of
ingenuity, serendip ity, and dogged determination. In an effort to
develop and discover better therapies against cancer, investigators
all over the world have increased our knowledge of cell biology,
biochemistry, and molecular biology. The goal has been to define
therapeuti cally exploitable differences between normal and
malignant cells. The result has been an increased understanding of
cellular and whole-organism biology and an increased respect for
the flexibility and resiliency ofbiologically systems. Thus, as
some new therapeutic targets have been defined and new therapeutic
strategies have been attempted, so have some new biological hurdles
resulting from tumor evasion of the intended therapeutic attack
been discovered. Historically, anticancer drugs have originated
from all available chemical sources. Synthetic molecules from the
chemical industry, especially dyestuffs and warfare agents, and
natural products from plants, microbes, and fungi have all been
potential sources of pharmaceuticals, including anticancer agents.
There is no shortage of molecules; the challenge has been and
continues to be methods of identifying molecules that have the
potential to be therapeutically important in human malignant
disease. "Screening" remains the most important and most
controversial method in cancer drug discovery. In vitro screens
have generally focused on cytotoxicity and have identified several
highly cytotoxic molecules. Other endpoints available in vitro are
inhibition of proliferation, 3 inhibition of [ H]thymidine
incorporation into DNA and various viability assays, based most
frequently on dye exclusion or metabolism.
General
Imprint: |
HumanaPress
|
Country of origin: |
United States |
Series: |
Cancer Drug Discovery and Development |
Release date: |
November 2010 |
First published: |
1997 |
Editors: |
Beverly A. Teicher
|
Dimensions: |
254 x 178 x 23mm (L x W x T) |
Format: |
Paperback
|
Pages: |
451 |
Edition: |
Softcover reprint of the original 1st ed. 1997 |
ISBN-13: |
978-1-61737-046-5 |
Categories: |
Books >
Medicine >
Other branches of medicine >
Pharmacology >
General
|
LSN: |
1-61737-046-0 |
Barcode: |
9781617370465 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.